Big cannabis in the UK

Is industry support for wider patient access motivated by promises of recreational market worth billions?
Wednesday, March 18, 2020

cannabis genomeThe BMJ has uncovered links between companies, campaign groups and individuals lobbying for wider patient access to cannabis for medical use and a parallel campaign to create a lucrative recreational market for the drug in the UK. The article focuses on the links between commercial organisations that are seeking new markets for recreational cannabis and patient groups and researchers. Some suggest that the debate is being fuelled by a growing breed of new companies, ranging from large scale cannabis growers and distributors in Canada to UK and international investment groups, which are manoeuvring to take advantage of a widely anticipated shift in the UK’s cannabis regulatory landscape.